LMNL Mar 25 '21 Transcript Seeking Alpha - some truth Liminal BioSciences, Inc. (LMNL) CEO Bruce Pritchard on Q4 2020 Results - Earnings Call Transcript
Liminal BioSciences, Inc. (LMNL) CEO Bruce Pritchard on Q4 2020 Results - Earnings Call Transcript | Seeking Alpha Mar. 25, 2021 11:31 PM ETLiminal BioSciences Inc. (LMNL) Liminal BioSciences, Inc. (NASDAQ:LMNL) Q4 2020 Earnings Conference Call March 25, 2021 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations and Communications Manager Bruce Pritchard - CEO Patrick Sartore - President Murielle Lortie - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Edwin Zhang - H.C. Wainwright & Co. Doug Loe - Leede Jones Gable Bruce Pritchard As previously communicated, we've been engaged in the process to find a commercialization partner for Ryplazim, which has to date not resulted in an executable transaction. We, therefore, commenced the process to evaluate potential strategic alternatives for our plasma-derived therapeutics business aimed at minimizing our cash burn. These alternatives may result in a divestment in whole or in part of the plasma-derived therapeutics business and/or other noncore assets or in other courses of action, including, but not limited to, other strategic transactions or the closure of our Ryplazim-related operations.
Patrick Sartore
Thank you, Bruce. Good morning, everyone. On the plasma-derived therapeutics business, we will continue to progress our evaluation of strategic alternatives for said business, including a divestment of the Ryplazim business and/or noncore assets related thereto, while continuing to work towards the PDUFA target action date of June 5, 2021 for Ryplazim.
Our plasma-derived therapeutics business unit personnel in regulatory affairs, clinical research, manufacturing and quality assurance are continuing preparations for the FDA's review, potential responses to further information requests and a potential pre-approval inspection by the FDA at our facilities. We are mindful of the potential impact of the continuing COVID-19 pandemic on FDA staff, and are working cooperatively with them to enable their review to be conducted in a timely manner, consistent with new PDUFA target action date.
Bruce Pritchard
Okay. I'll maybe start off on that, and then I can ask Patrick to step in as well. But as we said in our press release, we're -- we've made the strategic decision that we'd like to focus the business on our small molecule operations going forward. So we're looking to divest our plasma business in its entirety, whether that's in 1 or multiple transactions. So we're looking to divest the plasma centers, the manufacturing operations and the Ryplazim asset. So that's the nature of what we're looking for.
I think it's without giving anything away on what we're doing with negotiations and discussions that would be commercially sensitive. The reality is that we are looking at all opportunities here, whether we do this before or after Ryplazim approval.
There's the truth, Newcamo/Realstocky (same guy behind both boardnames)